US Pharm. 2015;40(9):5.

Silver Spring, MD—Addyi (flibanserin) has recently been approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Until now, there were no FDA-approved treatments for sexual desire disorders in women or men. HSDD is characterized by low sexual desire that causes significant distress or interpersonal difficulty and is not due to a coexisting psychiatric or medical condition, relationship problems, or drug effects. Addyi was approved with a Risk Evaluation Mitigation Strategy to assure safe use. Because Addyi can cause hypotension and syncope, which can be more severe in patients who consume alcohol, take certain CYP3A4 inhibitors, or have liver impairment, treatment will be available only through certified healthcare professionals and pharmacies.

To comment on this article, contact